Spanish Series of Patients Treated With the Radionuclide Lutetium177
SEPTRALU, Spanish Series of Patients Treated With the Radionuclide Lutetium177
Sociedad Española de Medicina Nuclear e Imagen Molecular
5,000 participants
May 10, 2021
OBSERVATIONAL
Conditions
Summary
This study aims to pool the clinical experience of Spanish centers treating patients with 177Lu-DOTATATE to evaluate the efficacy, tolerance, and safety of the drug in routine clinical practice and to learn about the profiles of patients and tumors treated and the results in each type of patient and tumor.
Eligibility
Inclusion Criteria3
- Written informed consent must be obtained prior to any data collection.
- Patients must be diagnosed with unresectable or metastatic, progressive, somatostatin receptor positive tumour
- Aged ≥18 years.
Exclusion Criteria1
- None
Interventions
Radiopharmaceutical solution for infusion (7.4 GBq of Lutathera per 30 ml vial)
Radiopharmaceutical solution for infusion (7.4 GBq of Lutathera per 30 ml vial)
Locations(20)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04949282